Session Information
Session Type: Abstract Submissions (ACR)
Background/Purpose
Sjögren’s syndrome (SS) is a complex autoimmune disease involving the salivary and lacrimal glands along with various systemic manifestations. It is a difficult disease to identify especially in its early stages. Average time from disease onset to diagnosis is 4.7 years. The serological markers suggested by the American College of Rheumatology for diagnosis of SS are antinuclear antibodies (ANA), rheumatoid factor (RF), anti-Ro, and anti-La. Novel SS autoantibodies, anti-salivary gland protein 1 (SP1), anti-carbonic anhydrase 6 (CA6) and anti-parotid secretory protein (PSP), often expressed earlier compared to traditional SS biomarkers, have been identified in animal studies and clinical trials. An approved diagnostic blood panel (Sjö™) incorporating classic and novel biomarkers was integrated as standard procedure in ophthalmic/optometric practices across 12 geographic markets.
Methods
Serum samples from patients with idiopathic dry eyes were analyzed with the Sjö™ panel through the end of May 2014. These patients had not previously been diagnosed with SS. Antibodies to RF, anti-Ro, anti-La, anti-SP1, anti-CA6 and anti-PSP were tested using enzyme linked immunosorbent assay. ANA was analyzed by indirect immunofluorescence using Hep-2 substrate.
Results
By the end of May 2014, 2306 samples had been analyzed. Of the dry eye patients analyzed, 608 (27%) turned out to be positive for SS markers. Of the positive patients, 62.6% were identified solely by the novel markers SP-1, CA6, and PSP. Only 13.2% of the patients were identified with solely the classic markers. Majority of samples were from women (88%), of whom 24% were positive for SS markers. In the subset of male dry eye patients tested (n=273), 64 were identified as positive for SS (23%).
Conclusion
The current data illustrates many patients with “idiopathic” dry eyes have autoantibodies consistent with early SS, at a frequency higher than currently reported in the literature. The majority of patients express the novel autoantibodies associated with an early stage of SS, anti-SP1, anti-CA6 and anti-PSP, without anti-Ro or anti-La. Earlier diagnosis of SS in these patients may lead to better management of their dry eye and other systemic manifestations via referral/co-management with rheumatologists and other health care providers.
Disclosure:
M. Jasek,
NiCox, S.A.,
1,
Nicox Inc,
3;
K. Malyavantham,
Immco Diagnostics,
3;
L. Suresh,
None;
J. Ambrus,
NiCox, S.A.,
2,
NiCox, S.A.,
5;
D. Pardo,
NiCox, S.A.,
1,
Nicox Inc,
3.
« Back to 2014 ACR/ARHP Annual Meeting
ACR Meeting Abstracts - https://acrabstracts.org/abstract/sjo-an-advanced-diagnostic-panel-for-detection-of-sjogrens-syndrome-autoantibodies/